2009
DOI: 10.1051/medsci/20092510847
|View full text |Cite
|
Sign up to set email alerts
|

Ischémie cérébrale

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2009
2009
2021
2021

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(2 citation statements)
references
References 35 publications
0
1
0
1
Order By: Relevance
“…With the development and implementation of the FAST-MAG approach and RSMP, we now have the opportunity to rapidly treat patients within the Golden-hour before there is extensive neuronal loss. Moreover, since recent research has proposed that pleiotropic agents may be required to treat stroke(3, 87, 88) in order to provide protection to the neurovascular unit(12, 52, 89), block multiple pathways of the ischemic cascade and possibly even activate trophic support mechanisms or provide neurotrophic support for recovery and regeneration, we have some insight into drug classes that may be most effective. Theoretically, all neuroprotectant drug candidates could be used immediately following patient presentation to offer the best chance of success.…”
Section: Neuroprotective Drug Research and Developmentmentioning
confidence: 99%
“…With the development and implementation of the FAST-MAG approach and RSMP, we now have the opportunity to rapidly treat patients within the Golden-hour before there is extensive neuronal loss. Moreover, since recent research has proposed that pleiotropic agents may be required to treat stroke(3, 87, 88) in order to provide protection to the neurovascular unit(12, 52, 89), block multiple pathways of the ischemic cascade and possibly even activate trophic support mechanisms or provide neurotrophic support for recovery and regeneration, we have some insight into drug classes that may be most effective. Theoretically, all neuroprotectant drug candidates could be used immediately following patient presentation to offer the best chance of success.…”
Section: Neuroprotective Drug Research and Developmentmentioning
confidence: 99%
“…Les Accidents Vasculaires cérébraux (AVC) sont la cause de nombreux décès dans le monde et la première cause de handicap moteur chez l'adulte (Feigin et al, 2014 ;Go et al, 2014). La thrombolyse est, aujourd'hui, le traitement de référence en cas de survenu d'une ischémie cérébrale (Bordet et al, 2009 ;Leys et al, 2009 ;Lamblin et al, 2018) responsable de 85% des AVC. Cependant, pour diverses raisons, elle ne peut être réalisée que sur quelques patients (Leys et al, 2009 ;Masingue et Alamowitch, 2014 ;Quintard, 2014).…”
Section: Introductionunclassified